Gene Editing

30 March -1 April 2020 | Business Design Centre London

 

 

2000+
Attendees
700+
1-2-1 Meetings
300+
Speakers
100+
Exhibitors
12
Streams

 

 

Gene Modified Cell Therapy

GENE MODIFIED CELL THERAPY, Tuesday 31 March 2020

CONFERENCE DAY 1 - TUESDAY 31st March 2020

Opening Keynotes Day 1 – CAR-T & Immunotherapy focus

08:45

Welcome – Jessica Robinson, Project Director, Advanced Therapies 2020, Terrapinn

Prasad Adusumilli
09:00

Keynote presentaton: Autologous Mesothelin-targeting CAR-T to tackle solid tumours in the clinic

  • The presentation will highlight results to date of mesothelin-targeted CAR T-cell clinical trial results
  • Advances in preclinical research of CAR T-cell therapy for solid tumors will be presented
  • Novel strategies for overcoming hurdles to solid tumor CAR T-cell therapy will be discussed
Panel discussion
Bradley Campbell
10:00

Importance of patient focus in developing gene therapy for rare diseases

10:20

Morning Coffee Break

Martin Pule
11:20

Keynote presentation: War in the Blood - the latest in the front line of CAR-T clinical research

Mark Sawicki
11:40

Effective Integration Strategies Through a Compliance Unified Ecosystem (CUE)

  • Systems Integration continues to be a major issue in the production and distribution of Advanced Therapies
  • Well-defined strategies for the integration of independent informatics platforms will be critical for future standardization and workflow optimization
  • Cryoport’s Compliance Unified Ecosystem (CUE) is driving standard practices for systems integration in the industry
round tables
12:00

Technology and Strategy Roundtables will run from 12:00-12:45 with 15 minutes for a quick summary from each table at the front of the room. These will take place in the conference rooms: look for you

Technology and Strategy Roundtables will run from 12:00-12:45 with 15 minutes for a quick summary from each table at the front of the room. These will take place in the conference rooms: look for your table number to participate.
1. Raw material supply for the commercial manufacturing of cell and gene therapies
Frank Hecht

Frank Hecht, Vice President Marketing And Sales, CellGenix GmbH

10. Exploring the crossover between human and veterinary applications for stem cells
Joanna Miller

Joanna Miller, Chief Scientific Officer, Cell Therapy Sciences

15. Industry-no profit alliances: how to optimize synergies
Elena Beltrami

Elena Beltrami, Business Development Manager, Fondazione Telethon

17. How companies can interact with the regulator and various pitfalls to be aware of
John Johnston

John Johnston, Clinical Assessor, Medicines & Healthcare Products Regulatory Agency

19. Roundtable available
2. Physiological conditions and analytical and monitoring tools for 3D cell cultivations
Cornelia Kasper

Cornelia Kasper, Professor, Biopharmaceutical Production And Technology, BOKU

3. Ensuring safe delivery to patients and fast time-to-market of advanced therapies - How to address challenges of drug administration, fill & finish, packaging & stability?
Diana Lober

Diana Lober, Product Manager, Schott AG

5. Considerations for manufacture scale-up from academia to commercial manufacturing
Johannes Van Der Loo

Johannes Van Der Loo, Clinical Vector Core Director, The Children's Hospital of Philadelphia

7. Reserved for Fujifilm Diosynth Biotechnology
13:00

Lunch

GENE MODIFIED CELL THERAPY

Solid Tumours

Dr David Gilham
GENE MODIFIED CELL THERAPY
14:20

Exploiting Natural Receptors to broaden the horizon of CAR-T

  • New clinical data for non-gene edited allogenic CAR-T targeting NKG2D in solid tumour applications
  • Update on data for autologous CAR-T for AML
  • SHRNA platform preclinical update and IND status
Steven Lee
GENE MODIFIED CELL THERAPY
14:40

Using CAR T-cells to target the tumour vasculature

Neill Moray Mackenzie
GENE MODIFIED CELL THERAPY
15:00

Taking Tumour infiltrating T cells into pivotal clinical studies

Avery Posey
GENE MODIFIED CELL THERAPY
15:20

Fundamentals of CAR-T cells: make them safe and make them potent

16:20

Afternoon Break

18:00

Close of Conference for the day - Please join us for an evening drinks reception

last published: 05/Mar/20 17:05

GENE MODIFIED CELL THERAPY, Wednesday 1 April 2020

CONFERENCE DAY 1 - WEDNESDAY 1st April 2020

Opening Keynotes Day 2 — The latest science in gene therapy and gene editing

Federico Mingozzi
09:00

Gene therapy 2.0: New clinical data, therapeutic applications and next generation technologies

  • Latest updates on LUXTURNA studies to treat blindness, haemophilia and rare disease
  • Tackling the challenges of viral gene therapies i.e. immunogenicity
  • Developing the next generation of gene therapies, what does the future hold?
Steve Kanner
09:20

Next-generation gene editing technology for allogeneic immune cell therapeutics

  • Next-generation CRISPR-Cas9 technology
  • Significantly enhanced editing specificity
  • Editing in immune cells for generation of functionally tuned therapeutics
09:40

Repairing the human genome with designed zinc finger editing reagents

  • Overview of Sangamo’s zinc finger protein gene editing technology, including new innovations that facilitate specificity, precision, and gene editing efficiency
  • Will address specific examples of defined therapeutic applications including the generation of reagents suitable for use in tauopathies, Huntington’s disease, and lysosomal storage diseases
Frederic Chereau
10:00

In vivo gene editing paediatric patients with rare diseases

10:20

Networking Refreshments

GENE MODIFIED CELL THERAPY

Off the shelf: Moving towards allogeneic models

Dr Bob Valamehr
GENE MODIFIED CELL THERAPY
11:20

Creation of off-the-shelf TCR-less CAR T cell therapies

Dr Bob Valamehr, Chief Development Officer, Fate Therapeutics
Ricardo Baptista
GENE MODIFIED CELL THERAPY
11:40

Automating and scaling manufacture of “off-the-shelf” engineered allogeneic CAR-T therapies

  • The presentation will highlight process steps that are a challenge to automate and scale.
  • Recent advances in developing our manufacturing process platform will be presented.
  • Analytical strategies to gain understanding and control of manufacturing process and product quality will be discussed.
Christina Coughlin
GENE MODIFIED CELL THERAPY
12:00

Developing the next suite of cellular therapies using engineered red cells using the latest technologies

David Pauza
GENE MODIFIED CELL THERAPY
12:20

ImmunoTox: Genetic manipulation of solid tumors to activate the natural γδ T cell response

Lawrence Lamb
GENE MODIFIED CELL THERAPY
12:40

Genetic engineering of drug-resistant gamma delta T cells for eradication of residual glioblastoma

  • Haploidentical gamma delta post-transplant immune “boost” and strategy for off the shelf therapy in glioblastoma trial
  • Drug Resistant Immunotherapy (DRI) - gamma delta T cells in combination with chemotherapy – allows superior targeting of residual glioblastoma.
  • Accrual and logistical information from ongoing trials.
13:00

Neworking Lunch

GENE MODIFIED CELL THERAPY

Gamma Delta T-Cells

Stewart Abbot
GENE MODIFIED CELL THERAPY
14:00

Gamma Delta T cells engineered with targeting moieties (CARs and TCRs) directed to cell surface and intracellular antigens

  • Development of engineered off-the-shelf allogeneic γδ T cell products
  • Preclinical efficacy and safety of chimeric antigen receptor-modified γδ T cell products
  • Large-scale cGMP-compliant manufacture of γδ T cell products
Jurgen Kuball
GENE MODIFIED CELL THERAPY
14:20

TEG’s as next generation of CAR

Conrad Russell Y Cruz
GENE MODIFIED CELL THERAPY
14:40

Engineering NK Cell Resistance to the Tumor Microenvironment

  • Role of TME-mediated immune suppression in tumor progression and its negative effects on NK cell function
  • Engineering NK cell resistance to TGF-beta
  • In vitro and in vivo function of gene modified NK cells
Mark Lowdell
GENE MODIFIED CELL THERAPY
15:00

Potentiation of the anti-tumour NK cell response in vitro and in vivo

Troels Jordansen
GENE MODIFIED CELL THERAPY
15:20

World’s first off-the-shelf NK cellular immunotherapy making cancer a chronic disease

  • How and why off-the-shelf?
  • Why are NK-cells important in cancer treatments?
  • Cancer management a viable option?
Stefanos Theoharis
GENE MODIFIED CELL THERAPY
15:40

Different approaches to allogeneic therapies

  • Allogeneic CAR approaches are being developed based on gene-edited T-cells, or different cell types, such as NK, NKT and gamma delta T-cells. Several of those are now in the clinic.
  • There are different technologies being used to generate these products, including for engineering, manufacturing and cell source.
  • This talk will offer a broad overview of the various efforts in the space and their key features.
16:00

Networking refreshments

18:00

Close of conference

last published: 05/Mar/20 17:05